Tackling Challenging Indications & Unmet Medical Need.

We are not afraid to go boldly into diseases and conditions for which few or no effective treatments have been developed. We love the challenge and accept the responsibility.

Our Pipeline

TRX103 (Treg)
(allo polyclonal,  off the shelf, non antigen-specific)

GvHD

Inflammatory bowel disease

Additional undisclosed indications

TRX319 (CAR Treg)
‍(allo polyclonal,  off the shelf,  antigen-specific)

Multiple B-cell mediated AID

TRX103 (Treg)
(allo polyclonal,  off the shelf, non antigen-specific)

Indication

GvHD

Research

Lead
Selection

IND
Enabling

Phase 1

Pivotal

TRX103 (Treg)
(allo polyclonal,  off the shelf, non antigen-specific)

Indication

Inflammatory bowel disease

Research

Lead
Selection

IND
Enabling

Phase 1

Pivotal

TRX103 (Treg)
(allo polyclonal,  off the shelf, non antigen-specific)

Indication

Additional undisclosed indications

Research

Lead
Selection

IND
Enabling

Phase 1

Pivotal

TRX319 (CAR Treg)
‍(allo polyclonal, off the shelf,  antigen-specific)

Indication

Multiple B-cell mediated AID

Research

Lead
Selection

IND
Enabling

Phase 1

Pivotal

mixture
hits

Lead
Identification

Desease
Validation

Lead
Optimization

Liver InflaMmation

2 Chemical Series

Neuroinflammation

5 Chemical Series

NF-kB / IL-1B signaling

29 Chemical series

NLRP3 inflammasome

1 Chemical series

Gut-restricted
fxr agonism

1 Chemical series

Gut-restricted
tgr5 agonism

1 Chemical series

Nav 1.7

1 Chemical series

PCSK 9

6 Chemical series

Ind-
enabling

Indication

Nash, Wilson's disease

Parkinson’s disease, als

Acute liver failure, multiple

Multiple

NASH, PBC, IBD

Type ii diabetes

Pain

Hypercholestrolemia

Partner with us

Our Programs

Our focus is on diseases with no effective treatment or cure.

Graft versus Host Disease (GvHD)

Graft versus Host Disease (GvHD) occurs due to pathogenic immune responses after hematopoetic stem cell transplants, frequently the only treatment for patients with aggressive hematological malignancies, such as acute myeloid leukemia.

~15%

Rate of severe acute Grade III-IV GvHD

For patients receiving peripheral blood stem cell transplants from mismatched donors.

M. M. Al Malki et al. BloodAdvances 5, 2650-2659 (2021).

>40%

Mortality rate for Grade III-IV aGvHD

Despite prophylactic regimens aimed at reducing incidence and severity, over one third of patients with aGvHD die as a result.

S. G. Holtan et al. Blood 140,LBA-4-LBA-4 (2022).

Inflammatory Bowel Disease

Severe refractory Inflammatory Bowel Disease (IBD) is a persistent, acute, symptomatic gut disease that continues to significantly impact the quality of life of patients despite continued use of anti-inflammatory or disease modifying drugs.

30%

Of IBD patients fail all lines of therapy

A significant portion of steroid refractory IDB patients never achieve disease control, significantly lowering their quality of life.

D. Wintjens et al. J of Crohn's and Colitis 15, 391-400(2020).

25%

Percent of Crohn's patients who will require
major surgery

Many Crohn's patients will ultimately require colectomies to alleviate symptoms, though this does not address the root cause of disease.

Tsai et al. Clin Gastroenterology andHepatology 19.10 (2021): 2031-2045.

B and T Cell Mediated Autoimmune Diseases

Systemic autoimmune diseases are characterized by aberrant adaptive immune responses to autoantigens. Autoreactive B and T cells play a central role in the pathogenesis of autoimmunity and have been implicated in a large number of autoimmune disorders.

>80

Number of defined B and T cell driven autoimmune disorders

This figure continues to rise as new diseases are uncovered and diagnosed.

Source: Johns Hopkins School of Medicine

>100Bn

Annual Cost Burden of AID in the US

This figure only includes 7 of the over 100 known B and T cell mediated autoimmune diseases, which continue to increase in prevalence.

Source: American Autoimmune Related Diseases Association (AARDA)

Relentlessly dedicated to improving the lives of patients.

We are pursuing breakthrough innovation in the spaces of autoimmunity and inflammation with a world-class team aiming to change the way devastating diseases are treated.

Get in Touch